Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150) …
PA Ascierto, D Stroyakovskiy, H Gogas… - The Lancet …, 2023 - thelancet.com
Background Primary analysis of the phase 3 IMspire150 study showed improved
investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib …
investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib …
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis …
R Gutzmer, D Stroyakovskiy, H Gogas, C Robert… - The Lancet, 2020 - thelancet.com
Background IMspire150 aimed to evaluate first-line combination treatment with BRAF plus
MEK inhibitors and immune checkpoint therapy in BRAF V600 mutation-positive advanced …
MEK inhibitors and immune checkpoint therapy in BRAF V600 mutation-positive advanced …
[HTML][HTML] Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
Background Emerging data suggest that the combination of MEK inhibitors and
immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated …
immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated …
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …
PA Ascierto, M Mandalà, PF Ferrucci… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …
R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - thelancet.com
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Background The combination of cobimetinib with vemurafenib improves progression-free
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …
[HTML][HTML] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
PF Ferrucci, AM Di Giacomo… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
(triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and …
First‐line atezolizumab monotherapy in patients with advanced BRAFV600 wild‐type melanoma
SJ de Azevedo, AC de Melo, L Roberts… - Pigment Cell & …, 2021 - Wiley Online Library
Anti‐programmed death‐1 agents are an established option for advanced melanoma, but
the anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibody atezolizumab, an agent …
the anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibody atezolizumab, an agent …
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib …
D Schadendorf, A Hauschild, M Santinami… - The Lancet …, 2019 - thelancet.com
Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with
BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or …
BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or …
[HTML][HTML] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
Background The BRIM-3 trial showed improved progression-free survival (PFS) and overall
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …